Pancreatic cancer medium and low differentiation is only the degree of differentiation of pancreatic cancer cells, and it can’t tell how many stages it is. Pancreatic cancer with low or middle differentiation is more malignant and more likely to have distant metastasis. The clinical staging of pancreatic cancer is mainly based on three factors: the size of pancreatic cancer mass, whether there is any metastasis in local lymph nodes and whether there is any metastasis in distant organs. If the pancreatic tumor is only confined to the pancreas and there is no metastasis in local lymph nodes and distant organs, the clinical staging should belong to stage I. If distant metastasis has already appeared, the clinical staging should belong to stage II. If distant metastasis has occurred, regardless of the size of the tumor and whether the regional lymph nodes have metastasis or not, the clinical staging should belong to stage IV. If there are local lymph node metastases, but the tumor has not invaded the celiac artery or the superior mesenteric artery, the staging at this time belongs to stage III. If the tumor has invaded the celiac artery or the superior mesenteric artery, regardless of whether the local lymph nodes have metastasized or not, the staging at this time belongs to stage III.